A cyclical exchange of citrate has been shown to exist in the intact organism, with the blood plasma serving as the transporting medium. In vivo studies have indicated a considerable uptake of citrate by the liver (1) and kidney (2), and a release of citrate into the blood by the peripheral tissues (1, 3) and intestine (4, 5) . Interest in the blood citrate flux has centered primarily around the importance of this intermediate in carbohydrate metabolism, in its relationship to calcium mobilization and deposition in bone (6), and in its role as a chelating agent for calcium in the urine (7, 8).
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The studies reported here have been concerned with an attempt to elucidate the metabolic fate of the blood citrate in rats with the aid of radioactive citrate. The data, obtained by following the pattern of respiratory C140, and the urinary excretion of radioactive carbon after the intravenous administration of sodium citrate-1,5-C'4, indicated a rapid turnover of the blood citrate. Three hours after injection of the labeled citrate, approximately 90 per cent of the radioactivity was recovered in the respiratory CO., and in the urinary citrate. Evidence for the utilization of blood citrate as a precursor of tissue components was provided by assaying the C14 content of protein and lipid of kidneys and liver after intravenous citrate-C14 administration.
In an effort to define further the metabolic fate of the blood citrate, inhibitors of citrate oxidation were administered prior to citrate-C14 administration. Peters (9) has shown that fluoroacetate inhibits the enzyme, aconitase, by virtue of its conversion to fluorocitrate. As a consequence of aconitase inhibition, the metabolism of citrate to isocitrate in the Krebs tricarboxylic acid cycle is blocked. In our experiments both fluoroacetate and fluorocitrate influenced the fate of the administered citrate-C14. In the intact animal the effects of each of the inhibitors were strikingly different: fluroacetate resulted in a decreased, and fluorocitrate resulted in an increased urinary excretion of citrate-C14. Tissue slice experiments confirmed this difference in the action of the inhibitors. In contrast to the postulate of Peters, the in vitro data are consistent with the view that fluoroacetate is also an inhibitor of the condensing enzyme.
MATERIALS AND METHODS
Fed, female Sprague-Dawley rats, weighing between 185 and 235 g, were used. Citric acid-1,5-C"' was obtained from Tracerlab, Inc., and sodium acetate--C1 '4 from Volk Radiochemical Co. Sodium fluoroacetate 1 was purchased from Bios Laboratories, Inc. Barium fluorocitrate, synthesized by the method of Rivett (10) , was obtained from the Sonbert Chemical Co., Brooklyn, N. Y.; this preparation contained less than 1 per cent barium citrate by specific analysis. Before use, the barium salt was dissolved in dilute HCl, the barium was precipitated with saturated sodium sulfate and the supernatant fluid was neutralized with dilute NaOH. Solutions of the fluoroinhibitors were freshly prepared prior to use.
In the in vivo experiments, sodium citrate-1,5-C"4 in isotonic saline was given intravenously in a volume of 0.3 ml. Collection of respiratory CO2 was accomplished by drawing CO2-free air through a glass metabolism jar containing the rat, and the respiratory CO2 was trapped in NaOH. Barium carbonate precipitates were prepared from aliquots of the NaOH solutions. After the BaCO3 was washed with water and then alcohol, it was plated and counted in a Nuclear-Chicago gas-flow counter with a Micromil window. Urine collections were made up to standard volume, and aliquots were taken for direct plating and for conversion of the carboxyl groups of the urinary citrate to CO2 with ceric sulfate (11) Fractionation of liver and kidney tissues to determine the intracellular distribution of citrate was carried out by a modification of the method of Schneider (17) . A 10 per cent (wt/vol) homogenate of the tissue was prepared in 0.25 M sucrose with a motor-driven Teflon pestle or with a Dounce homogenizer at 0C. A portion of the whole homogenate was stored at 00 until the end of the separation procedure. Further fractionation of the whole homogenate was accomplished by centrifuging at 700 G for 10 minutes at 50C. The supernatant solution was removed and the sediment was resuspended in 0.25 M sucrose, homogenized, and centrifuged at 700 G for 10 minutes. This supernatant was combined with the supernatant from the first centrifugation and the sediment was resuspended in water and homogenized; this nuclear fraction was stored at 00 until the end of the fractionation procedure. The combined supernatants were then spun at 5°for 10 minutes at 5,000 G to sediment the mitochondria. The supernatant and the fluffy layer containing microsomes and soluble cytoplasm were removed, and this fraction is referred to as the extramitochondrial fraction. The sediment, representing the mitochondrial fraction, was resuspended and homogenized in distilled water. Appropriate aliquots of each of the fractions were added to equal volumes of 10 per cent trichloroacetic acid and the protein was removed by centrifugation. Citrate determinations in the presence of sucrose were carried out by a modification of the pentabromacetone procedure (18) .
RESULTS
The fate of intravenously administered citrate-C14 in the intact rat. Initially, the rates of conversion of 4 ug of citrate-C'4 (1.1 X 105 cpm) and 125 jug of citrate-C'4 (5.6 X 106 cpm) to respiratory CO, and urinary citrate were compared in order to determine whether the larger quantity of citrate could be administered without significantly altering the physiological state (Table I) . The rate of conversion of the radioactive carbon of citrate-C14 to respiratory CO2 and the percentage of the administered label in the urinary citrate were independent of the amount of citrate-C14 ad- [4] Fluoroacetate [4] Fluorocitrate [3] Fluorocitrate [3] (2.5 mg/kg) (20 (Figure 3 ). On the other hand, fluorocitrate administration resulted in a depression (p < 0.001 at 20 and 40 mg per kg) of respiratory Cl402 from labeled citrate.
The effect of these fluoroinhibitors on endogenous citrate metabolism and the fate of administere(l citrate-C14 was further studied by examining the urine and blood of these animals (Table  111) Intracellular distribution of citrate after fluoroinhibitor administration. Additional information concerning citrate metabolism was obtained by studying citrate accumulation in subcellular components of kidney and liver tissue after administration of each of the fluoroinhibitors to rats (Table  V) . In control animals, the preponderance of tissue citrate was localized in the mitochondrial fraction of kidney and liver. After administration of fluoroacetate to rats, approximately 60 per cent of the liver citrate was found in the mitochondrial fraction, in confirmation of the data of Schneider, Striebich and Hogeboom (18) . In most instances the remainder of the tissue citrate could be accounted for in the nuclear fraction and in the fraction not sedimented by centrifuging at 5,000 G for 10 minutes. Essentially the same distribution of citrate in liver tissue was found in the fluorocitrate-treated animal. In contrast, about one-half to two-thirds of kidney citrate was recovered in the fraction not sedimenting at 5,000 G for 10 minutes when either fluoroacetate or fluorocitrate was administered to the animal; the balance of the tissue citrate was found in the mitochondrial and nuclear fractions. Tissue fractionation with 0.88 M sucrose, isotonic saline, 7. 
DISCUSSION
These investigations revealed that the blood citrate is metabolized at a rapid rate, as indicated by following the fate of intravenously injected radioactive citrate. By 3 hours, 55 per cent of the label was found in the respiratory C02; of the total radioactivity administered, 35 per cent was recovered in the urinary citrate. Thus, about 85 per cent of the citrate-C14 that remained in the animal was metabolized to C140. in 3 hours. This rate approaches that seen after administration of acetate-1-C14 to rats (22) . The rapid turnover of the blood citrate dictates that there is an equally rapid outflux from the tissues. A similar respiratory C1402 pattern was obtained by Lussier (23) after the intraperitoneal injection of 2 mg radioactive citric acid; only 10 per cent of the administered label was recovered in the urine in 8 hours, in contrast to the findings reported here. Since urinary citrate-C14 excretion is markedly depressed when 1.5 mEq of HCl is introduced into the stomach prior to injection of citrate-C14 (20) , it seems likely that the low levels obtained in the earlier experiments were due to the administration of the radioactive compound as the free acid.
Evidence (23) . Peters (9) has demonstrated that fluoroacetate is converted to fluorocitrate by biological systems, with consequent inhibition of the enzyme, aconitase. Other studies (19) , however, indicated that these two compounds did not result in equivalent inhibitory activities when administered to rats.
It was shown that fluorocitrate, but not fluoroacetate, resulted in an appreciable accumulation of citrate in the livers of male rats, in contrast to the findings in female rats (Table II) . Further, citrate accumulation in the heart was considerably greater after fluoroacetate than fluorocitrate administration. The present study of the effect of fluoroacetate and fluorocitrate on citrate metabolism provides additional evidence for the divergent action of these two inhibitors in vivo and in tissue slices.
In the intact animal, conversion of citrate-C'4 to respiratory C1402 was enhanced by pretreatment with fluoroacetate despite inhibition of citrate metabolism, as evidenced by accumulation of citrate in the tissues. In animals pretreated with fluorocitrate, conversion of citrate-C'4 to respiratory C140, was depressed; in this case the amount of citrate that had accumulated within the tissues was far less than that observed in the fluoroacetate-treated rats. These seemingly paradoxical findings were partially resolved upon analysis of the urinary excretion of the labeled citrate. In the one instance, fluoroacetate markedly inhibited the urinary excretion of the radioactive carbon, while fluorocitrate treatment resulted in an increased urinary excretion of radioactive carbon. Because of this, more radioactive citrate was available for oxidation to respiratory C1402 in the fluoroacetate-treated rat than in the normal and fluorocitrate-treated rat. In the fluoroacetatepoisoned rat one might expect that the administered radioactive citrate would be diluted to a large extent by the increased concentration of citrate in the tissues, with a consequent decreased rate of oxidation of the citrate-C'4 to C1402. Since this was not the case, the existence of more than one pool of citrate within the organism is suggested.
Another difference in the action of these fluoroinhibitors was noted; fluorocitrate, unlike fluoroacetate, caused striking increases in total urinary citrate excretion. Since the blood citrate levels were markedly elevated in both the fluoroacetateand fluorocitrate-treated rats, the data indicate that the renal tubular mechanism for handling citrate is affected diversely by each of the fluoroinhibitors that was tested.
Further confirmation of the difference in tissue responsiveness to fluorocitrate and fluoroacetate was obtained from in vitro tissue-slice ex-periments. The data indicate that fluoroacetate served as a more effective inhibitor of acetate oxidation than of citrate oxidation in both liver and kidney slices. This observation is in agreement with the finding of decreased acetate utilization by slices of heart, kidney and liver when fluoroacetate was present in the incubation medium (24) . In other experiments Kalnitsky (25) Although the distribution of citrate in the subcellular fractions of liver differed from that found in kidney after fluoroinhibitor administration, the localization in each of the tissues was the same, regardless of whether the rat received fluoroacetate or fluorocitrate.
